Carcinoma, Non-Small-Cell-Lung, Nonsmall Cell Lung Cancer, Non-Small Cell Lung Cancer
Conditions
Brief summary
The purpose of this research study is to study the safety and immune response of people who receive a personalized dendritic cell vaccine with the intention of stimulating the immune system to react to lung cancer cells.
Detailed description
Tumor vaccines represent a promising area of clinical investigation in solid tumors based on evidence of clinical activity and minimal toxicity. The underlying hypothesis of this research is that immunization against tumor neoantigens is effectively required to elicit antigen-reactive T cells capable of recognizing and eliminating cancer. Moreover, both quantitative and qualitative improvements in CD8 immunity are necessary (but not sufficient) for clinical response and improved survival. The goal of this study is to build on our prior clinical trial results in melanoma by studying the immune response to tumor neoantigens in patients with stage 1 NSCLC.
Interventions
PROCEDUREStandard of care surgery
PROCEDUREApheresis
DRUGCyclophosphamide
BIOLOGICALPersonalized mature dendritic cell vaccine
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with completely resected stage I non-small cell lung cancer who are not considered for adjuvant post operative therapy. * Age ≥ 18 years. * ECOG performance status 0-1. * HLA-A2 positive. * Required initial laboratory values (submitted within 14 days prior to registration): * WBC \> 3,000/mm3 * Hg ≥ 9.0 gm/dL * Platelets \>75,000/mm3 * Serum bilirubin \< 2.0 mg/dL * Serum creatinine \< 2.0 mg/dL * Sexually active women of childbearing potential must use effective birth control during the trial and for at least two months following the trial, and sexually active men must be willing to avoid fathering a new child while receiving therapy. * Able to understand and willing to sign an IRB-approved written informed consent document.
Exclusion criteria
* Prior treatment with cytotoxic chemotherapy * Prior treatment with targeted therapy or immunotherapy. * Active untreated CNS metastasis. * Active infection. * Prior malignancy (except non-melanoma skin cancer) within 3 years. * Pregnant or nursing. * Concurrent treatment with systemic corticosteroids; local (inhaled or topical) steroids are permitted. * Known allergy to eggs. * Prior history or uveitis or autoimmune inflammatory eye disease. * Known positivity for hepatitis B sAg, hepatitis C antibody, or HIV antibody.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunological response as measured by increased numbers of peptide specific CD8+ T cells as calculated by the tetramer assay | 1 year | -Blood for immunological response is drawn every week from Dose #1 to 6 weeks after Dose #3 (Day 1 to Day 126 = Week 18 and then every 4 weeks until Day 365) |
| Safety and tolerability of vaccine as measured by adverse events experienced and graded by NCI CTCAE Version 4.0 | 30 days after last vaccine (approximately Day 115) | Safety will be closely monitored after vaccination. Patients will be observed for 2 hours after the first dose and vital signs recorded every 30 minutes during that time period beginning at the start of the infusion. For each dose thereafter, patients will be observed in the treatment area for 30 minutes after the infusion. The following parameters will be assessed: * Local signs and symptoms * Systemic signs and symptoms * Laboratory evaluations * Adverse and serious adverse events * Toxicity will be graded according to the NCI's CTCAE version 4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to progression (TTP) | 5 years | These patients have been completed resected so there is no tumor response to monitor. CT scans evaluating for progression will be performed at baseline, following the third vaccine dose, and as per routine care during follow-up (generally every 3 months for the first year and every 6 months for the next 4 years thereafter). |
Outcome results
None listed